Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
PMID: 31617907
2020
The Journal of antimicrobial chemotherapy
Abstract: Among the 29 relatively common INSTI-selected mutations, 24 emerged as candidates for inclusion on a list of INSTI surveillance drug-resistance mutations: T66A/I/K, E92G/Q, G118R, F121Y, E138A/K/T, G140A/C/S, Y143C/H/R/S, S147G, Q148H/R/K, N155H, S230R and R263K.
Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naive patients: A single-centre experience.
PMID: 31518723
2020
Journal of global antimicrobial resistance
Abstract: Transmitted INSTI mutations (Q148H and G140S) responsible for high-level resistance to raltegravir and elvitegravir and intermediate resistance to dolutegravir and bictegravir were found, for the first time, in two individuals.
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
PMID: 31330378
2020
Journal of global antimicrobial resistance
Abstract: The major INSTI-RMs that more frequently emerged were: N155H (17.8%), G140S (8.4%), Y143R (7.5%), Q148H (6.5%), and Y143C (4.7%).
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Abstract: Overall, the Q148H/K/R plus G140A/C/S and/or E138A/K/T pattern, defining an intermediate level of resistance to DTG, was detected in 70 (15%) cases.
Abstract: The most frequent INSTI resistance mutation was N155H, followed by Q148H/K/R, G140A/C/S, E138A/K/T and Y143C/H/R.
Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.
PMID: 30648124
2019
Open forum infectious diseases
Introduction: DTG appears to have a high genetic barrier to resistance, unlike the other drugs within the INSTI class, raltegravir and elvitegravir, which select for major resistance mutations such as N155H, Y143H/R/C, G140A/S, and Q148H/R/K.
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
PMID: 30753573
2019
The Journal of antimicrobial chemotherapy
Abstract: INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.
PMID: 30803972
2019
Antimicrobial agents and chemotherapy
Abstract: HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred <=5-fold changes in bictegravir susceptibility.
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
PMID: 31037930
2019
Revista espanola de quimioterapia
Abstract: Predominant major mutations were N155H (35.1%), Q148H/R (15.8%) and G140A/S (14%).
Introduction: Different pathways against first-generation InSTIs were identified whose primary mutations include the substitutions N155H, Q148K/R/H, and Y143R/C.
Result: Predominant combinations of mutations were 140A/S + Q148H/R and N155H + G163K/R.
Result: Predominant major integrase resistance mutations were N155H (35.1%), Q148H/R (15.8%) and PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary INSTI resistance (-R) substitutions were T66I/A/K, E92Q/G, T97A, F121Y, Y143R/H/C, S147G, Q148H/K/R, N155H/S and R263K in IN.
Result: Primary INSTI-R substitutions were infrequent (2.5%, 13/519) and consisted of T97A (1.7%, 9/519) and E92G, Q148H, S147G or Y143H (0.2%, 1/519 ea
Table: Q148H
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
PMID: 31169022
2019
AIDS research and human retroviruses
Abstract: INSTI DRM Q148H/K/R declined from 39.3% (2010) to 13.8% (2017).
HIV mutation literature information.
PMID: 
2020
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT